| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | TNF receptor-associated factor 2;6.3.2.-;E3 ubiquitin-protein ligase TRAF2;Tumor necrosis factor type 2 receptor-associated protein 3;TRAF2;TRAP3; |
| Cellular Localization | |
| Clonality | |
| Concentration | |
| Form | Liquid |
| Host | |
| Immunogen | A synthesized peptide derived from human TRAF2 |
| Isotype | |
| Molecular Weight | |
| Product Type | |
| Reactivity | |
| Reconstitution | |
| Storage | |
| Target | |
| UniProt # |
Overview
This product is an anti-TRAF2 antibody for target detection and characterization. Key identifiers include host species: Rabbit; Monoclonal; clone 26T29; isotype IgG; reactivity: Human. Reported application contexts include WB, IHC, ICC, IF, IP, Flow (as provided in the source record). Boster Bio Anti-TRAF2 Rabbit Monoclonal Antibody catalog # M00400-2. Tested in WB, IHC, ICC/IF, IP, Flow Cytometry applications. This antibody reacts with Human.
Key elements and design rationale
- Target: TRAF2 (TNF receptor-associated factor 2).
- Antibody format: Monoclonal; clone 26T29; isotype IgG.
- Host: Rabbit.
- Species reactivity: Human (confirm in your model system with appropriate controls).
This description is intended to help interpret the antibody design and the biological context of the target using the fields provided in the catalog record, alongside general experimental considerations.
Biological background
TRAF2 (protein: T-cell surface glycoprotein CD4) is a commonly studied target in molecular and cellular biology. Functional context (as provided): Regulates activation of NF-kappa-B and JNK and plays a central role in the regulation of cell survival and apoptosis. Required for normal antibody isotype switching from IgM to IgG. Has E3 ubiquitin-protein ligase activity and promotes 'Lys-63'- linked ubiquitination of target proteins, such as BIRC3, RIPK1 and TICAM1. Is an essential constituent of several E3 ubiquitin- protein ligase complexes, where it promotes the ubiquitination of target proteins by bringing them into contact with other E3 ubiquitin ligases. Regulates BIRC2 and BIRC3 protein levels by inhibiting their autoubiquitination and subsequent degradation; this does not depend on the TRAF2 RING-type zinc finger domain. Plays a role in mediating activation of NF-kappa-B by EIF2AK2/PKR. In complex with BIRC2 or BIRC3, promotes ubiquitination of IKBKE. . Reported cellular localization context: Cytoplasm . Tissue expression notes (as provided): Released primarily from activated T lymphocytes.
Research relevance and current trends
- Research context keywords from the source record include: Adapters,Apoptosis,Associated Proteins,Atherosclerosis,Cancer,Cardiovascular,Cell Biology,Cytoplasmic,Growth Factors,Growth Factors/Hormones,Intracellular,NFKB Pathway,Nuclear Signaling,Signal Transduction,Signaling Pathway,Vascular Inflammation.
- Current studies often focus on connecting target abundance/localization to pathway perturbations across models, tissues, and cell states.
- Quantitative and multiplexed assays (e.g., imaging + immunoblot panels) are commonly used to compare phenotypes across conditions and time-courses.
Common research applications
- Western blotting (WB): assess relative target abundance across samples, treatments, or time-points.
- Immunohistochemistry (IHC): evaluate spatial distribution of target-positive staining in tissue architecture.
- Immunofluorescence/ICC (IF/ICC): visualize subcellular localization patterns and cell-to-cell heterogeneity.
- Flow cytometry: quantify target-positive populations and compare shifts in marker distributions.
- Immunoprecipitation (IP): enrich target complexes for downstream immunoblot or interaction analyses.
Workflow ideas (metafield): Validate TRAF2 antibody specificity using KO/KD control samples (WB/IF/IHC as appropriate), Detect TRAF2 expression by Western blot in cell or tissue lysates, Detect TRAF2 in FFPE tissue sections by immunohistochemistry, Localize TRAF2 by immunofluorescence/immunocytochemistry in cultured cells, Quantify TRAF2-positive cells by flow cytometry in single-cell suspensions, Enrich TRAF2 by immunoprecipitation from lysates for downstream analysis
Notes for experimental interpretation
- Consider isoforms and post-translational modifications (PTMs) that may shift apparent molecular weight or epitope accessibility.
- Apparent molecular weight may vary by sample type and processing (observed MW: 56 kDa; calculated MW: 55859 MW).
- Control concepts: include appropriate negative controls (e.g., isotype, KO/KD samples) and orthogonal validation when feasible.
Additional product details (from the source record)
- Molecular weight (observed): 56 kDa
- Cellular localization (provided): Cytoplasm .
- Tissue details (provided): Released primarily from activated T lymphocytes.
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
